<p>AbbVie（纽约证券交易所：ABBV - 获取免费报告）在周五上午发布了其 2024 年第二季度盈利指引的更新。公司为该时期提供了每股盈利指引为 2.530-2.570，而共识每股盈利预估为 3.050。公司发布了营收指引为-。AbbVie 还将其 2024 财年指引更新为 10.610-10.810 美元每股盈利。</p>
<h2>AbbVie 股价上涨 1.3%</h2>
<ul>
<li>AbbVie 股票：投资者购买的绝佳机会</li>
</ul>
<p>AbbVie 股票在周五午间交易中上涨了 2.16 美元，达到 166.00 美元。该股交易量为 993,954 股，相比其平均交易量 5,621,344 股。公司的 50 天简单移动平均线为 164.43 美元，200 天简单移动平均线为 167.77 美元。公司市值为 2931.3 亿美元，市盈率为 48.89，PEG 比为 2.10，β值为 0.64。AbbVie 的 12 个月最低价为 132.70 美元，最高价为 182.89 美元。公司的资产负债比为 7.93，流动比率为 0.94，速动比率为 0.83。</p>
<p>AbbVie（纽约证券交易所：ABBV - 获取免费报告）上次发布季度盈利数据是在 5 月 3 日周五。公司报告该季度每股盈利为 2.31 美元，超过每股盈利预估 2.26 美元 0.05 美元。该季度公司营收为 123.1 亿美元，相比共识预估的 119.3 亿美元。AbbVie 的净利润率为 11.02%，净资产回报率为 179.47%。公司营收同比增长 0.7%。在去年同期的同一季度，公司每股盈利为 2.46 美元。股票分析师预计 AbbVie 在本财年将发布 11.27 美元的每股盈利。</p>
<h2>AbbVie 股息公告</h2>
<ul>
<li>投资生物科技：高风险可能带来高回报</li>
</ul>
<p>该公司最近宣布每季度股息，将于 8 月 15 日星期四支付。截至 7 月 15 日星期一持股人将获得每股 1.55 美元的股息。除息日为 7 月 15 日星期一。这代表年化基础上的 6.20 美元股息和 3.73% 的股息率。AbbVie 的派息比率为 183.98%。</p>
<h2>分析师升级和降级</h2>
<p>几位股票研究分析师对该股发表了评论。BMO Capital Markets 将 AbbVie 的目标股价从 195.00 美元降至 180.00 美元，并在 4 月 29 日星期一的研究报告中为该公司设定了超买评级。巴克莱将 AbbVie 的价格目标从 195.00 美元降至 187.00 美元，并在 4 月 29 日星期一的研究报告中为该公司设定了超重评级。Piper Sandler Companies 重申了对 AbbVie 的超买评级，并在周三的研究报告中设定了 190.00 美元的价格目标。Cantor Fitzgerald 重申了对 AbbVie 的超买评级，并在 6 月 20 日星期四的研究报告中设定了 200.00 美元的价格目标。最后，Guggenheim 将 AbbVie 的目标股价从 188.00 美元上调至 190.00 美元，并在 3 月 22 日星期五的报告中为该股设定了买入评级。两位股票研究分析师对该股进行了持有评级，十二位发出了买入评级，一位给予该公司强烈买入评级。根据 MarketBeat.com 的数据，AbbVie 目前的共识评级为中等买入，平均目标股价为 181.07 美元。</p>
<ul>
<li>两家增长潜力巨大的仿制药制造商</li>
</ul>
<p><strong>阅读我们关于 ABBV 的最新股票分析</strong></p>
<h2>关于 AbbVie（获取免费报告）</h2>
<p>AbbVie Inc 在全球范围内发现、开发、生产和销售药品。公司提供 Humira，用于治疗自身免疫和肠道贝赫切特病以及脓疱病；Skyrizi 用于治疗中度至重度斑块状银屑病、银屑病和克罗恩病；Rinvoq 用于治疗类风湿和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴突关节病、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血液癌症患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血液癌症。</p>
<h2>精选故事</h2>
<ul>
<li>我们比 AbbVie 更喜欢的五只股票</li>
<li>如何投资保险公司：指南</li>
<li>星座品牌股票 2025 年第一季度：击败安海斯 - 布希？</li>
<li>如何投资 FAANG 股票</li>
<li>高通股票在负面新闻面前持续上涨</li>
<li>股票板块对成功投资的重要性</li>
<li>具有稳定增长机会的前三只夏季股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 揭示：3 CENT 加密货币将于 6 月 24 日爆发？（来自 True Market Insiders）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDgz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDgz"/></p>
<h2>您现在是否应该投资 1000 美元购买 AbbVie 股票？</h2>
<p>在考虑 AbbVie 之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 AbbVie 不在名单上。</p>
<p>尽管 AbbVie 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票是更好的选择。</p>
<p>查看这五只股票</p>

艾伯维

<p>AbbVie 更新了其 2024 年第二季度收益预测，提供了每股收益指导范围为 2.530-2.570，而市场普遍预期为 3.050。该公司还将其 2024 年全年指导范围更新为每股收益 10.610-10.810。在公告后，AbbVie 股票上涨了 1.3%</p>

<p>AbbVie (NYSE:ABBV - Get Free Report) issued an update on its second quarter 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 2.530-2.570 for the period, compared to the consensus earnings per share estimate of 3.050. The company issued revenue guidance of -. AbbVie also updated its FY 2024 guidance to 10.610-10.810 EPS.</p>
<div class="lb-trans"><p>AbbVie（纽约证券交易所：ABBV - 获取免费报告）在周五上午发布了其 2024 年第二季度盈利指引的更新。公司为该时期提供了每股盈利指引为 2.530-2.570，而共识每股盈利预估为 3.050。公司发布了营收指引为-。AbbVie 还将其 2024 财年指引更新为 10.610-10.810 美元每股盈利。</p>
</div><h2>AbbVie Trading Up 1.3 %</h2>
<ul>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
</ul>
<div class="lb-trans"><h2>AbbVie 股价上涨 1.3%</h2>
<ul>
<li>AbbVie 股票：投资者购买的绝佳机会</li>
</ul>
</div><p>AbbVie stock traded up $2.16 during midday trading on Friday, reaching $166.00. The stock had a trading volume of 993,954 shares, compared to its average volume of 5,621,344. The firm's fifty day simple moving average is $164.43 and its two-hundred day simple moving average is $167.77. The firm has a market cap of $293.13 billion, a price-to-earnings ratio of 48.89, a PEG ratio of 2.10 and a beta of 0.64. AbbVie has a twelve month low of $132.70 and a twelve month high of $182.89. The company has a debt-to-equity ratio of 7.93, a current ratio of 0.94 and a quick ratio of 0.83.</p>
<div class="lb-trans"><p>AbbVie 股票在周五午间交易中上涨了 2.16 美元，达到 166.00 美元。该股交易量为 993,954 股，相比其平均交易量 5,621,344 股。公司的 50 天简单移动平均线为 164.43 美元，200 天简单移动平均线为 167.77 美元。公司市值为 2931.3 亿美元，市盈率为 48.89，PEG 比为 2.10，β值为 0.64。AbbVie 的 12 个月最低价为 132.70 美元，最高价为 182.89 美元。公司的资产负债比为 7.93，流动比率为 0.94，速动比率为 0.83。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, May 3rd. The company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.26 by $0.05. The company had revenue of $12.31 billion for the quarter, compared to the consensus estimate of $11.93 billion. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. The business's revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.46 EPS. Equities analysts anticipate that AbbVie will post 11.27 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>AbbVie（纽约证券交易所：ABBV - 获取免费报告）上次发布季度盈利数据是在 5 月 3 日周五。公司报告该季度每股盈利为 2.31 美元，超过每股盈利预估 2.26 美元 0.05 美元。该季度公司营收为 123.1 亿美元，相比共识预估的 119.3 亿美元。AbbVie 的净利润率为 11.02%，净资产回报率为 179.47%。公司营收同比增长 0.7%。在去年同期的同一季度，公司每股盈利为 2.46 美元。股票分析师预计 AbbVie 在本财年将发布 11.27 美元的每股盈利。</p>
</div><h2>AbbVie Dividend Announcement</h2>
<ul>
<li>Investing in Biotech: High Risk for a Potentially High Reward</li>
</ul>
<div class="lb-trans"><h2>AbbVie 股息公告</h2>
<ul>
<li>投资生物科技：高风险可能带来高回报</li>
</ul>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be given a dividend of $1.55 per share. The ex-dividend date is Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.73%. AbbVie's payout ratio is 183.98%.</p>
<div class="lb-trans"><p>该公司最近宣布每季度股息，将于 8 月 15 日星期四支付。截至 7 月 15 日星期一持股人将获得每股 1.55 美元的股息。除息日为 7 月 15 日星期一。这代表年化基础上的 6.20 美元股息和 3.73% 的股息率。AbbVie 的派息比率为 183.98%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several equities research analysts have commented on the stock. BMO Capital Markets lowered their target price on shares of AbbVie from $195.00 to $180.00 and set an outperform rating for the company in a research note on Monday, April 29th. Barclays lowered their price objective on shares of AbbVie from $195.00 to $187.00 and set an overweight rating for the company in a research report on Monday, April 29th. Piper Sandler Companies reissued an overweight rating and set a $190.00 price objective on shares of AbbVie in a research report on Wednesday. Cantor Fitzgerald reissued an overweight rating and set a $200.00 price objective on shares of AbbVie in a research report on Thursday, June 20th. Finally, Guggenheim increased their target price on shares of AbbVie from $188.00 to $190.00 and gave the stock a buy rating in a report on Friday, March 22nd. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of Moderate Buy and an average price target of $181.07.</p>
<ul>
<li>2 Generic Drug Makers With Growing Runways</li>
</ul>
<div class="lb-trans"><p>几位股票研究分析师对该股发表了评论。BMO Capital Markets 将 AbbVie 的目标股价从 195.00 美元降至 180.00 美元，并在 4 月 29 日星期一的研究报告中为该公司设定了超买评级。巴克莱将 AbbVie 的价格目标从 195.00 美元降至 187.00 美元，并在 4 月 29 日星期一的研究报告中为该公司设定了超重评级。Piper Sandler Companies 重申了对 AbbVie 的超买评级，并在周三的研究报告中设定了 190.00 美元的价格目标。Cantor Fitzgerald 重申了对 AbbVie 的超买评级，并在 6 月 20 日星期四的研究报告中设定了 200.00 美元的价格目标。最后，Guggenheim 将 AbbVie 的目标股价从 188.00 美元上调至 190.00 美元，并在 3 月 22 日星期五的报告中为该股设定了买入评级。两位股票研究分析师对该股进行了持有评级，十二位发出了买入评级，一位给予该公司强烈买入评级。根据 MarketBeat.com 的数据，AbbVie 目前的共识评级为中等买入，平均目标股价为 181.07 美元。</p>
<ul>
<li>两家增长潜力巨大的仿制药制造商</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on ABBV</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ABBV 的最新股票分析</strong></p>
</div><h2>About AbbVie (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 AbbVie（获取免费报告）</h2>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>AbbVie Inc 在全球范围内发现、开发、生产和销售药品。公司提供 Humira，用于治疗自身免疫和肠道贝赫切特病以及脓疱病；Skyrizi 用于治疗中度至重度斑块状银屑病、银屑病和克罗恩病；Rinvoq 用于治疗类风湿和银屑病性关节炎、强直性脊柱炎、特应性皮炎、轴突关节病、溃疡性结肠炎和克罗恩病；Imbruvica 用于治疗成人血液癌症患者；Epkinly 用于治疗淋巴瘤；Elahere 用于治疗癌症；Venclexta/Venclyxto 用于治疗血液癌症。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than AbbVie</li>
<li>How to Invest in Insurance Companies: A Guide</li>
<li>Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Qualcomm Stock Continues to Rise in the Face of Negative News</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Top 3 Summer Stocks with Solid Growth Opportunities</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们比 AbbVie 更喜欢的五只股票</li>
<li>如何投资保险公司：指南</li>
<li>星座品牌股票 2025 年第一季度：击败安海斯 - 布希？</li>
<li>如何投资 FAANG 股票</li>
<li>高通股票在负面新闻面前持续上涨</li>
<li>股票板块对成功投资的重要性</li>
<li>具有稳定增长机会的前三只夏季股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders)(Ad)</p>
<div class="lb-trans"><p>→ 揭示：3 CENT 加密货币将于 6 月 24 日爆发？（来自 True Market Insiders）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NDgz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8483&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in AbbVie right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 AbbVie 股票？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 AbbVie 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 AbbVie 不在名单上。</p>
</div><p>While AbbVie currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 AbbVie 目前在分析师中有 “中等买入” 评级，但顶级分析师认为这五只股票是更好的选择。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

艾伯维（NYSE:ABBV）发布 2024 年第二季度收益预期